Precision medicine in MDS: tailoring treatment through molecular profiling

This VJHemOnc podcast explores how precision medicine is reshaping the management of myelodysplastic syndromes (MDS). Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses whole genome sequencing, patient selection for venetoclax-based therapy, and the future of precision medicine following the VERONA trial (NCT04401748). Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, reviews the evolving role of luspatercept, while Sophie Park, MD, PhD, CHU Grenoble Alpes, Grenoble, France, presents Phase III EPO-PRETAR (NCT03223961) findings. Mika Kontro, MD, PhD, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland, discusses updated BEXMAB trial (NCT05428969) results of bexmarilimab plus azacitidine. Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, explores TP53-mutated MDS, and Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights first-in-human data for the CLK inhibitor BH-30236 in relapsed or refractory AML and higher-risk MDS.